NCT07136142View on ClinicalTrials.gov

A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Malignant Solid Tumor
Interventions
DRUG

FH-006 for Injection

FH-006 for injection.

Trial Locations (2)

200032

Fudan University Shanghai Cancer Center, Shanghai

300181

Tianjin Medical Unversity Cancer Institute & Hospital, Tianjin

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY